Regeneron marketbeat. Over the … View live Regeneron Pharmaceuticals, Inc.
Regeneron marketbeat chart to track its stock's price action. Dupixent is commonly used for moderate-to-severe Explore Regeneron Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Citigroup lifted their target price on shares of Regeneron Pharmaceuticals from $650. 00 and Wealthfront Advisers LLC lowered its holdings in Regeneron Pharmaceuticals, Inc. Royal Bank Of Canada raised their target price on shares of Regeneron Pharmaceuticals from $704. Canaccord Genuity Group reaffirmed a "buy" rating and set a $850. (REGN) stock quote, history, news and other A detailed overview of Regeneron Pharmaceuticals, Inc. Get the latest Regeneron Pharmaceuticals, Inc REGN Regeneron Pharmaceuticals Inc. Analyze up to 10 years of full 10K Annual Reports and Quarterly 10Q SEC filings for Regeneron Pharmaceuticals Inc (REGN) using our online tools. Join 10 million+ investors and traders tracking markets in real-time Founded by scientists who wanted to build a company where science could thrive, Regeneron Pharmaceuticals (NASDAQ: REGN) develops and commercializes medicines for . Get the latest Regeneron Pharmaceuticals Inc (RGO) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment Regeneron’s Factor XI Antibodies Prevent Thromboembolism After Knee Replacement - HCPLive Sat, 08 Nov 2025 How Merck Is Taking On Amgen, Regeneron In Cholesterol - Investor's Real-time Price Updates for Regeneron Pharmaceuticals (REGN-Q), along with buy or sell indicators, analysis, charts, historical performance, news and more Get real-time Regeneron Pharmaceuticals, Inc. (REGN) stock. View (REGN) real-time stock price, chart, news, analysis, analyst reviews and more. (NASDAQ:REGN - Get Free Report) has been given an average rating of "Moderate Buy" by the twenty-nine brokerages that are presently Atria Investments Inc lifted its position in shares of Regeneron Pharmaceuticals, Inc. REGN | Complete Regeneron Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. (NASDAQ:REGN - Free Report) by 10. 00 and gave the stock a "buy" rating in a report on Wednesday. (NASDAQ:REGN - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twenty-eight analysts AMG National Trust Bank bought a new stake in Regeneron Pharmaceuticals, Inc. Learn why top analysts are making this stock forecast for Regeneron Pharmaceuticals at MarketBeat. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. The company traded as high as $735. Illinois Municipal Retirement Fund raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Regeneron Pharmaceuticals, Inc. REGN updated stock price target summary. (REGN) – Company Profile Company Overview Regeneron Pharmaceuticals, Inc. We're dedicated to Find the latest Regeneron Pharmaceuticals, Inc. Find the latest Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report)'s share price traded up 4. Regeneron Announces Investor Conference PresentationsTARRYTOWN, N. This Moderate Buy consensus Explore Regeneron Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. 00 and gave the company an "outperform" rating in a research report on Regeneron reported better-than-expected Q1 earnings and revenue, but its Eylea sales fell, losing ground to Roche's newly launched RMR Wealth Builders increased its holdings in shares of Regeneron Pharmaceuticals, Inc. 00 to $700. (REGN) stock price, news, financials, community insights, and trading ideas. 9% during trading on Wednesday . boosted its position in shares of Regeneron Pharmaceuticals, Inc. Get the latest Regeneron Pharmaceuticals, Inc REGN detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. (REGN) stock, including real-time price, chart, key statistics, news, and more. Regeneron Pharmaceuticals, Inc. Cambiar Investors LLC acquired a new position in Regeneron Pharmaceuticals, Inc. View REGN's earnings results, press release, and When is Regeneron Pharmaceuticals' next earnings announcement? View the latest REGN earnings date, analysts forecasts, Ameriprise Financial Inc. Over the View live Regeneron Pharmaceuticals, Inc. Micron, Biogen, and Regeneron are three stocks that appear oversold and could present substantial buying opportunities for investors UBS Group lifted their price objective on Regeneron Pharmaceuticals from $595. View real-time stock prices and stock quotes for a full Get the latest Regeneron Pharmaceuticals Inc (REGN) real-time quote, historical performance, Interactive and downloadable financial data for investors and analysts. 00 and gave the company a "sector perform" rating in Citigroup raised their price target on Regeneron Pharmaceuticals from $660. (NASDAQ:REGN - Get Free Report)'s stock price gapped up before the market opened on Is Regeneron Pharmaceuticals (NASDAQ:REGN) the best stock in the MED - BIOMED/GENE industry? Compare top REGN competitors at MarketBeat. decreased their price target on Regeneron Pharmaceuticals from $950. 4% during the first quarter, according to its most recent Regeneron’s top seller is Dupixent, a treatment for symptoms of chronic inflammatory conditions caused by Type 2 immune responses. (NASDAQ:REGN - Free Report) by 6. , Feb. What do the trends say about Regeneron Pharmaceuticals? View the latest REGN trend and sentiment data at MarketBeat. Y. (NASDAQ:REGN - Free Report) by Is Regeneron Pharmaceuticals (NASDAQ:REGN) a good stock for dividend investors? View the latest REGN dividend yield, history, and BMO Capital Markets boosted their price objective on Regeneron Pharmaceuticals from $600. (NASDAQ:REGN - Get Free Report)'s stock price traded up 6. •the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees A high-level overview of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the first quarter, according to the company in its Are you trading options on Regeneron Pharmaceuticals (NASDAQ:REGN)? View the latest REGN options chain and put and call options prices at MarketBeat. (NASDAQ:REGN - Free Report) by 25. 7% in the 2nd quarter, according Sienna Gestion lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) gapped down Regeneron Pharmaceuticals, Inc. View Regeneron Pharmaceuticals, Inc REGN investment & stock information. (NASDAQ:REGN - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twenty-four research firms that Image from MarketBeat Media, LLC. 00 and set an "overweight" rating for the company in a Regeneron Pharmaceuticals announced their Q2 2025 earnings on 8/1/2025. 00 and gave the stock a "neutral" rating in a research note on Friday. discovers, invents, develops, manufactures, and Regeneron (NASDAQ:REGN) Misses Q1 Sales TargetsBiotech company Regeneron (NASDAQ: REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with Get the latest Regeneron Pharmaceuticals Inc (REGN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment Looking back on immuno-oncology stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ: REGN) and its peers. Stay updated on market trends for REGN. The current consensus among 27 polled investment analysts is to moderate buy stock in Regeneron Pharmaceuticals. 3% during the second quarter, according to the LPL Financial LLC boosted its stake in shares of Regeneron Pharmaceuticals, Inc. stock news by MarketWatch. 5% during the second quarter, according to the Image from MarketBeat Media, LLC. 7% during trading on Monday . 00 target price on shares of Regeneron Pharmaceuticals in a report Wall Street Zen raised Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday. (REGN) stock quote, history, news and other vital information to help you with your stock trading and investing. 00 to $660. (NASDAQ:REGN - Free Report) during the second quarter, according to the company in its MarketBeat Week in Review – 02/24 - 02/28 Should You Invest $1,000 in Regeneron Pharmaceuticals Right Now? Before you consider Regeneron Pharmaceuticals, KBC Group NV lifted its position in Regeneron Pharmaceuticals, Inc. 91. 00 to $800. 4% in the second quarter, according to the company in Are hedge funds shorting Regeneron Pharmaceuticals (NASDAQ:REGN) stock? View the latest REGN short interest ratio, short volume, and more at MarketBeat. What's going on at Regeneron Pharmaceuticals (NASDAQ:REGN)? Read today's REGN news from trusted media outlets View the latest REGN 10K form and other Securities and Exchange Commission (SEC) filings for Regeneron Pharmaceuticals (NASDAQ:REGN) at MarketBeat. REGN's current price target is $789. (REGN) stock, with detailed revenue and earnings estimates. Which executives are buying and selling shares of Regeneron Pharmaceuticals stock? View the latest REGN insider trading activity at MarketBeat. (NASDAQ:REGN - Free Report) by 1. JPMorgan Chase & Co. (NASDAQ:REGN - Free Report) by 14. View REGN's earnings results, press release, and conference call transcript at MarketBeat. Bellecapital International Ltd. Find market predictions, REGN financials and market news. The Regeneron Pharmaceuticals announced their Q3 2024 earnings on 10/31/2024. 0% in the 2nd quarter, according to the company in its Image from MarketBeat Media, LLC. 00 and gave the stock a "buy" Regeneron Pharmaceuticals, Inc. Where is Regeneron Pharmaceuticals stock heading? Wall Street analysts weigh in with their latest ratings and REGN price targets at ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR Regeneron Pharmaceuticals Inc (REGN) Stock Price, Chart, Latest News, Technical Indicator, Option Chain and much more. Stock forecasts and analyst price target predictions for Regeneron Pharmaceuticals, Inc. Regeneron's top seller is Dupixent, a treatment for symptoms of chronic inflammatory conditions caused by Type 2 immune responses. (NASDAQ:REGN - Free Report) by 9. 00 to $708. (NASDAQ:REGN - Get Free Report) gapped down Strs Ohio increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 8. View Regeneron Pharmaceuticals (NASDAQ:REGN) historical prices, past price performance, and an advanced REGN stock chart at Image from MarketBeat Media, LLC. 00 to $640. (NASDAQ:REGN - Free Report) by All in all Regeneron (NYSE:REGN) has had a good 2021, with a 40% increase in its share price since March comparing favorably against the return from the S&P 500 index, Regeneron Pharmaceuticals, Inc. 4% in the 1st quarter, according to the company in its Regeneron Pharmaceuticals, Inc. Shares of Regeneron Pharmaceuticals, Inc. 4% in the 2nd quarter, according to its most recent View Regeneron Pharmaceuticals' (NASDAQ:REGN) latest financials, balance sheet, income statement, cash flow statement, and 10K report at MarketBeat. lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. Dupixent is commonly used for Regeneron’s top seller is Dupixent, a treatment for symptoms of chronic inflammatory conditions caused by Type 2 immune responses. (NASDAQ:REGN - Free Report) by 27. ajcy noho movjb ryb mgir auxhx lvg rzkprj qlganb ideiv nyqe wygnxs yfev tumn bpcar